Sutro Biopharma, Inc. (NASDAQ:STRO) Receives $14.86 Average PT from Analysts

Shares of Sutro Biopharma, Inc. (NASDAQ:STRO) have received an average recommendation of “Buy” from the seven research firms that are presently covering the stock, Marketbeat reports. Seven investment analysts have rated the stock with a buy rating. The average 12 month target price among brokerages that have covered the stock in the last year is $13.71.

Several analysts have issued reports on STRO shares. Wedbush lowered their target price on shares of Sutro Biopharma from $12.00 to $8.00 and set an “outperform” rating on the stock in a research note on Tuesday. HC Wainwright reduced their target price on Sutro Biopharma from $16.00 to $12.00 and set a “buy” rating for the company in a research report on Tuesday. Oppenheimer reaffirmed an “outperform” rating and issued a $10.00 price target on shares of Sutro Biopharma in a report on Wednesday. Finally, JMP Securities reissued a “market outperform” rating and set a $17.00 price objective on shares of Sutro Biopharma in a report on Tuesday.

Insider Transactions at Sutro Biopharma

In related news, insider Nicki Vasquez sold 12,185 shares of Sutro Biopharma stock in a transaction on Monday, January 29th. The shares were sold at an average price of $5.00, for a total value of $60,925.00. Following the transaction, the insider now owns 12,803 shares in the company, valued at approximately $64,015. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Company insiders own 6.90% of the company’s stock.

Institutional Trading of Sutro Biopharma

Several hedge funds and other institutional investors have recently bought and sold shares of the stock. Nisa Investment Advisors LLC increased its stake in shares of Sutro Biopharma by 14,125.8% in the fourth quarter. Nisa Investment Advisors LLC now owns 8,820 shares of the company’s stock worth $38,000 after buying an additional 8,758 shares during the period. Wells Fargo & Company MN boosted its holdings in shares of Sutro Biopharma by 331.7% during the fourth quarter. Wells Fargo & Company MN now owns 5,690 shares of the company’s stock worth $46,000 after purchasing an additional 4,372 shares during the period. Point72 Hong Kong Ltd bought a new stake in shares of Sutro Biopharma in the second quarter worth about $46,000. Tower Research Capital LLC TRC increased its holdings in Sutro Biopharma by 342.3% during the 3rd quarter. Tower Research Capital LLC TRC now owns 15,128 shares of the company’s stock valued at $52,000 after purchasing an additional 11,708 shares during the period. Finally, Ergoteles LLC bought a new position in Sutro Biopharma during the 2nd quarter valued at approximately $54,000. Institutional investors own 96.99% of the company’s stock.

Sutro Biopharma Stock Performance

Shares of STRO opened at $4.93 on Friday. The stock’s 50-day simple moving average is $4.47 and its 200 day simple moving average is $3.77. Sutro Biopharma has a 52-week low of $2.01 and a 52-week high of $6.11. The stock has a market capitalization of $300.48 million, a price-to-earnings ratio of -2.77 and a beta of 0.95.

About Sutro Biopharma

Sutro Biopharma, Inc operates as a clinical-stage oncology company. It develops site-specific and novel-format antibody drug conjugates (ADC) that enables its proprietary integrated cell-free protein synthesis platform, XpressCF and XpressCF+. The company's product candidates include STRO-001, an ADC directed against the cancer target CD74 for patients with multiple myeloma and non-Hodgkin lymphoma that is in Phase 1 clinical trials; and STRO-002, an ADC directed against folate receptor-alpha for patients with ovarian and endometrial cancers, which is in Phase 1 clinical trials.